Reducing the Burden and Improving QoL in Non-Cystic Fibrosis Bronchiectasis: Insights on Challenging Cases

Program Overview

Patient Case Module 2 of 2

Non-cystic fibrosis bronchiectasis (NCFBE) is an irreversible, chronic lung disease in which patients experience airway dilation and bronchial wall injury secondary to repeated infections and inflammation, posing highly variable but potentially major health burdens to patients and society. There are no approved therapies specifically indicated for its treatment. In this activity, an interprofessional expert panel tackles difficult cases in NCFBE that have been crowdsourced from practicing clinicians all over the United States. What would you do? Listen as they describe diagnostic and treatment challenges and how healthcare professionals can work as a team to overcome them.

Link to Panel Discussion

Link to Module 1

0.25 CE Credit(s)

Expires: January 9, 2024

Target Audience

Pulmonology, infectious diseases, primary care, and radiology clinicians managing patients with NCFBE.

Educational Objectives

Upon completion of this activity, participants should be better able to:

Utilize clinical practice guidelines for non-cystic fibrosis bronchiectasis (NCFBE) diagnosis
Integrate the unique roles and responsibilities of the interprofessional care team when diagnosing and treating patients with NCFBE
Examine emerging treatments targeting the underlying immune mediated pathophysiologic processes of NCFBE

Activity Faculty

Mark L. Metersky, MD, FCCP (Chair)

Professor, Medicine
Associate Chief of Service, Department of Medicine
Chief, Division of Pulmonary, Critical Care and Sleep Medicine
Director, Center for Bronchiectasis Care
UConn Health
Farmington, CT